Influence of value of minimal residual disease at risk of developing recurrence of relapse in patients with acute lymphoblastic leukemia
https://doi.org/10.29235/1814-6023-2019-16-2-202-215
Abstract
Minimal residual disease (MRD) is the most significant predictor of the relapse in patients with acute lymphoblastic leukemia (ALL). MRD evaluation is necessary not only for the prediction of the relapse, but for additional stratification of patients by the risk groups in order to address the issue of the therapy individualization and to evaluate the therapy quality. This study analyzes the MRD parameters in patients with ALL at the stage of induction therapy and evaluates the effect of the value of the minimum residual disease on survival rates and the risk of relapse in patients with ALL treated according to protocol ALL-MB 2008.
About the Authors
E. A. Stolyarova
Republican Research Center for Pediatric Oncology, Hematology and Immunology
Belarus
Belarus
Elena A. Stolyarova – Hematologist
43, Frunzenskaya Str., 223053, v. Borovliany, Minsk Region
N. V. Migal
Republican Research Center for Pediatric Oncology, Hematology and Immunology
Belarus
Belarus
Nataliya V. Migal – Ph. D. (Med.), Assistant Professor, Head of the Department
43, Frunzenskaya Str., 223053, v. Borovliany, Minsk Region
M. V. Belevtsev
Republican Research Center for Pediatric Oncology, Hematology and Immunology
Belarus
Belarus
Mikhail V. Belevtsev – Ph. D. (Biol.), Assistant Professor, Deputy Director
43, Frunzenskaya Str., 223053, v. Borovliany, Minsk Region
L. V. Movchan
Republican Research Center for Pediatric Oncology, Hematology and Immunology
Belarus
Belarus
Ludmila V. Movchan – Ph. D. (Biol.), Immunologist
43, Frunzenskaya Str., 223053, v. Borovliany, Minsk Region
O. I. Budanov
Republican Research Center for Pediatric Oncology, Hematology and Immunology
Belarus
Belarus
Oleg I. Budanov – Medical statistic
43, Frunzenskaya Str., 223053, v. Borovliany, Minsk Region
A. M. Popov
National Medical Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev
Russian Federation
Russian Federation
Aleksandr M. Popov – Ph. D. (Med.), Head of the Laboratory
1, Zamora Machel Str., 117997, Moscow
L. G. Fechina
Regional Children’s Clinical Hospital no. 1
Russian Federation
Russian Federation
Larisa G. Fechina – Ph. D. (Med.), Head of the Department, Deputy Chief Doctor
32, Serafma Deryabina str., 620149, Yekaterinburg
O, V. Aleinikova
Republican Research Center for Pediatric Oncology, Hematology and Immunology
Belarus
Belarus
Olga V. Aleinikova – Corresponding Member, D. Sc. (Med.), Professor, Director
43, Frunzenskaya Str., 223053, v. Borovliany, Minsk Region
References
1. Metayer C., Milne E., Clavel J., Infante-Rivard C., Petridou E., Taylor M. [et al.]. The childhood leukemia international consortium. Cancer Epidemiology, 2013, vol. 37, no. 3, pp. 336–347. https://doi.org/10.1016/j.canep.2012.12.011
2. Ward E., DeSantis C., Robbins A., Kohler B., Jemal A. Childhood and adolescent cancer statistics, 2014. CA: a Cancer Journal for Clinicians, 2014, vol. 64, no. 2, pp. 83–103. https://doi.org/10.3322/caac.21219
3. Belson M., Kingsley B., Holmes A. Risk factors for acute leukemia in children: a review. Environmental Health Perspectives, 2007, vol. 115, no. 1, pp. 138–145. https://doi.org/10.1289/ehp.9023
4. Cools J. Improvements in the survival of children and adolescents with acute lymphoblastic leukemia. Haematologica, 2012, vol. 97, no. 5, pp. 635. https://doi.org/10.3324/haematol.2012.068361
5. Pui C.-H., Evans W. E. Acute lymphoblastic leukemia. New England Journal of Medicine, 1998, vol. 339, no. 9, pp. 605–615. https://doi.org/10.1056/NEJM199808273390907
6. Cooper S. L., Brown P. A. Treatment of pediatric acute lymphoblastic leukemia. Pediatric Clinics of North America, 2015, vol. 62, no. 1, pp. 61–73. https://doi.org/10.1016/j.pcl.2014.09.006
7. Locatelli F., Schrappe M., Bernardo M. E., Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood, 2012, vol. 120, no. 14, pp. 2807–2816. https://doi.org/10.1182/blood-2012-02-265884
8. Lee J. W., Cho B. Prognostic factors and treatment of pediatric acute lymphoblastic leukemia. Korean Journal of Pediatrics, 2017, vol. 60, no. 5, pp. 129–137. https://doi.org/10.3345/kjp.2017.60.5.129
9. Teachey D. T., Hunger S. P. Predicting relapse risk in childhood acute lymphoblastic leukaemia. British Journal of Haematology, 2013, vol. 162, no. 5, pp. 606–620. https://doi.org/10.1111/bjh.12442
10. Gaipa G., Basso G., Biondi A., Campana D. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Cytometry Part B Clinical Cytometry, 2013, vol. 84, nо. 6, pp. 359–369. https://doi.org/10.1002/cyto.b.21101
11. Schultz K. R., Pullen D. J, Sather H. N., Shuster J. J., Devidas M., Borowitz M. J. [et al.]. Risk- and response-based classifcation of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood, 2007, vol. 109, no. 3, pp. 926–935. https://doi.org/10.1182/blood-2006-01-024729
12. Lauten M., Möricke A., Beier R., Zimmermann M., Stanulla M., Meissner B. [et al.]. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica, 2012, vol. 97, no. 7, pp. 1048–1056. https://doi.org/10.3324/haematol.2011.047613
13. Schrappe M., Reiter A., Ludwig W. D., Harbott J., Zimmermann M., Hiddemann W. [et al.]. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALLBFM 90. Blood, 2000, vol. 95, no. 11, pp. 3310–3322.
14. Szczepański T., Orfão A., van der Velden V. H., San Miguel J. F., van Dongen J. J. Minimal residual disease in leukaemia patients. Lancet Oncology, 2001, vol. 2, no. 7, pp. 409–417.
15. Campana D. Determination of minimal residual disease in leukaemia patients. British Journal of Haematology, 2003, vol. 121, no. 6, pp. 823–838. https://doi.org/10.1046/j.1365-2141.2003.04393.x
16. van Dongen J. J., van der Velden V. H., Brüggemann M., Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood, 2015, vol. 125, no. 26, pp. 3996–4009. https://doi.org/10.1182/blood-2015-03-580027
17. Brüggemann M., Raff T., Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood, 2012, vol. 120, no. 23, pp. 4470–4481. https://doi.org/10.1182/blood-2012-06-379040
18. Chatterjee T., Mallhi R. S., Venkatesan S. Minimal residual disease detection using flow cytometry: applications in acute leukemia. Medical Journal Armed Forces India, 2016, vol. 72, no. 2, pp. 152–156. https://doi.org/10.1016/j.mjaf.2016.02.002
19. Ikoma M. R.V., Beltrame M. P., Ferreira S. I., Souto E. X., Malvezzi M., Yamamoto M. Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia. Revista Brasileira de Hematologia e Hemoterapia, 2015, vol. 37, no. 6, pp. 406–413. https://doi.org/10.1016/j.bjhh.2015.07.012
20. Campana D., Pui C.-H. Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia. Blood, 2017, vol. 129, no. 4, pp. 1913–1918. https://doi.org/10.1182/blood-2016-12-725804
21. Campana D. Molecular determinants of treatment response in acute lymphoblastic leukemia. Hematology. American Society of Hematology. Education Program, 2008, no. 1, pp. 366–373. https://doi.org/10.1182/asheducation-2008.1
22. Borowitz M. J., Devidas M., Hunger S. P., Bowman W. P., Carroll A. J., Carroll W. L. [et al.]. Clinical signifcance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood, 2008, vol. 111, no. 12, pp. 5477–5485. https://doi.org/10.1182/blood-2008-01-132837
23. Cavé H., van der Werff ten Bosch J., Suciu S., Guidal C., Waterkeyn C., Otten J. [et al.]. Clinical signifcance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. New England Journal of Medicine, 1998, vol. 339, no. 9, pp. 591–598. https://doi.org/10.1056/NEJM199808273390904
24. Van Dongen J. J., Seriu T., Panzer-Grümayer E. R., Biondi A., Pongers-Willemse M. J., Corral L. [et al.]. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet, 1998, vol. 352, no. 9142, pp. 1731–1738. https://doi.org/10.1016/S0140-6736(98)04058-6
25. Krejci O., van der Velden V. H., Bader P., Kreyenberg H., Goulden N., Hancock J. [et al.]. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplantation, 2003, vol. 32, no. 8, pp. 849–851. https://doi.org/10.1038/sj.bmt.1704241
26. Bader P., Kreyenberg H., Henze G. H., Eckert C., Reising M., Willasch A. [et al.]. Prognostic value of minimal residual disease quantifcation before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. Journal of Clinical Oncology, 2009, vol. 27, no. 3, pp. 377–384. https://doi.org/10.1200/JCO.2008.17.6065
27. Vora A. J., Goulden N., Mitchell C. D., Hough R., Rowntree C., Richards S. M. UKALL 2003, a randomised trial investigating treatment intensifcation for children and young adults with minimal residual disease defned high risk acute lymphoblastic leukaema. Blood, 2012, vol. 120, no. 21, pp. 136–136.
28. Conter V., Bartram C. R., Valsecchi M. G., Schrauder A., Panzer-Grümayer R., Möricke A. [et al.]. Molecular response to treatment redefnes all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood, 2010, vol. 115, no. 16, pp. 3206–3214. https://doi.org/10.1182/blood-2009-10-248146
29. Rumyantsev A. G. Results of prospective cooperative studies of the effectiveness of cancer treatment in children in Russia. Available at: https://docplayer.ru/91149045-Rezultaty-prospektivnyh-kooperirovannyh-issledovaniy-effektivnostilecheniya-raka-u-detey-v-rossii.html (accessed 7 February 2011) (in Russian).
Review
For citations:
Stolyarova E.A., Migal N.V., Belevtsev M.V., Movchan L.V., Budanov O.I., Popov A.M., Fechina L.G., Aleinikova O.V. Influence of value of minimal residual disease at risk of developing recurrence of relapse in patients with acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2019;16(2):202-215. (In Russ.) https://doi.org/10.29235/1814-6023-2019-16-2-202-215
Views: 733
Email this article 